Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$71.13 -0.9%	$70.72	$61.24 ▼ $87.68	$220.60B	0.37	5.28 million shs	2.73 million shs
BMY Bristol Myers Squibb	$46.91 -3.3%	$47.51	$39.93 ▼ $63.33	$95.36B	0.36	12.83 million shs	13.67 million shs
CSLLY CSL	$79.11 -2.0%	$78.95	$70.22 ▼ $109.00	$76.61B	0.79	72,123 shs	39,452 shs
NVO Novo Nordisk A/S	$68.93 -2.9%	$70.35	$57.00 ▼ $143.49	$307.77B	0.64	7.33 million shs	6.51 million shs
SNY Sanofi	$48.61 -1.5%	$50.05	$45.80 ▼ $60.12	$119.21B	0.48	2.33 million shs	1.21 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	0.00%	+2.20%	-5.16%	+7.30%	-8.51%
BMY Bristol Myers Squibb	0.00%	-0.22%	-7.44%	-7.43%	+14.09%
CSLLY CSL	0.00%	-1.06%	-0.04%	+7.12%	-21.91%
NVO Novo Nordisk A/S	0.00%	-0.17%	-14.97%	+6.45%	-51.71%
SNY Sanofi	0.00%	-0.56%	-4.37%	-5.61%	-4.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	3.7571 of 5 stars	3.4	5.0	1.7	0.0	3.5	0.0	1.3
BMY Bristol Myers Squibb	4.8877 of 5 stars	3.2	3.0	4.2	4.0	2.6	3.3	1.3
CSLLY CSL	1.4897 of 5 stars	0.0	5.0	1.7	0.0	1.1	0.0	1.3
NVO Novo Nordisk A/S	4.6352 of 5 stars	4.1	4.0	2.5	0.0	2.9	0.0	3.1
SNY Sanofi	4.1428 of 5 stars	3.6	4.0	2.5	0.0	2.7	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.83	Moderate Buy	$89.00	25.12% Upside
BMY Bristol Myers Squibb	2.32	Hold	$57.69	22.97% Upside
CSLLY CSL	4.00	Strong Buy	N/A	N/A
NVO Novo Nordisk A/S	2.27	Hold	$112.00	62.48% Upside
SNY Sanofi	3.11	Buy	$61.50	26.52% Upside

Current Analyst Ratings Breakdown

Latest BMY, AZN, SNY, NVO, and CSLLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
7/9/2025	AZN AstraZeneca	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$97.00
7/2/2025	SNY Sanofi	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/3/2025	SNY Sanofi	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$56.00
4/28/2025	NVO Novo Nordisk A/S	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	SNY Sanofi	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sell
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.08	$6.29 per share	11.30	$13.18 per share	5.40
BMY Bristol Myers Squibb	$48.30B	1.98	$5.89 per share	7.96	$8.08 per share	5.81
CSLLY CSL	$14.80B	5.18	$3.98 per share	19.89	$20.07 per share	3.94
NVO Novo Nordisk A/S	$42.12B	7.31	$3.90 per share	17.67	$4.66 per share	14.79
SNY Sanofi	$44.46B	2.68	$5.33 per share	9.12	$33.20 per share	1.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.49	28.57	14.23	1.31	14.14%	33.14%	12.83%	7/29/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.57	7.70	2.35	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
CSLLY CSL	$2.64B	N/A	0.00	19.34	1.71	N/A	N/A	N/A	8/19/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.39	14.79	1.34	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
SNY Sanofi	$6.02B	$2.80	17.36	10.23	1.11	14.56%	17.15%	9.80%	7/31/2025 (Estimated)

Latest BMY, AZN, SNY, NVO, and CSLLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.89	N/A	N/A	N/A	$77.51 billion	N/A
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/31/2025	Q2 2025	SNY Sanofi	$0.98	N/A	N/A	N/A	$9.91 billion	N/A
7/29/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	$14.08 billion	N/A
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.90%	N/A	82.73%	N/A
BMY Bristol Myers Squibb	$2.48	5.29%	N/A	92.88%	17 Years
CSLLY CSL	$1.20	1.52%	N/A	N/A	N/A
NVO Novo Nordisk A/S	$1.64	2.38%	N/A	48.52%	N/A
SNY Sanofi	$1.60	3.29%	N/A	57.14%	N/A

Latest BMY, AZN, SNY, NVO, and CSLLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.90	0.70
BMY Bristol Myers Squibb	2.65	1.28	1.17
CSLLY CSL	0.45	1.86	0.85
NVO Novo Nordisk A/S	0.70	0.74	0.56
SNY Sanofi	0.16	1.37	0.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BMY Bristol Myers Squibb	76.41%
CSLLY CSL	0.03%
NVO Novo Nordisk A/S	11.54%
SNY Sanofi	14.04%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BMY Bristol Myers Squibb	0.09%
CSLLY CSL	N/A
NVO Novo Nordisk A/S	0.07%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CSLLY CSL	32,698	968.42 million	N/A	Not Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
SNY Sanofi	82,878	2.45 billion	2.43 billion	Optionable

BMY, AZN, SNY, NVO, and CSLLY Headlines

Recent News About These Companies

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports

July 12 at 12:20 PM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

July 12 at 10:00 AM | prnewswire.com

U.S. Capital Wealth Advisors LLC Buys New Holdings in Sanofi (NASDAQ:SNY)

July 12 at 4:29 AM | marketbeat.com

Sanofi’s Phase 2 Study on SAR444656: A Potential Game-Changer for Atopic Dermatitis

July 11 at 12:57 PM | tipranks.com

Sanofi’s Amlitelimab Study: A Long-Term Look at Atopic Dermatitis Treatment

July 11 at 12:57 PM | tipranks.com

Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough for Lichen Simplex Chronicus

July 11 at 12:07 PM | tipranks.com

Sanofi’s Promising Phase 2 Study on SAR447537 for AATD Emphysema: A Potential Game-Changer

July 11 at 12:07 PM | tipranks.com

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

July 11 at 11:12 AM | benzinga.com

Brown Advisory Inc. Increases Holdings in Sanofi (NASDAQ:SNY)

July 11 at 4:56 AM | marketbeat.com

Concurrent Investment Advisors LLC Sells 28,246 Shares of Sanofi (NASDAQ:SNY)

July 11 at 4:27 AM | marketbeat.com

Leerink Partnrs Has Pessimistic View of Sanofi Q2 Earnings

July 11 at 2:15 AM | americanbankingnews.com

Sanofi’s Chlamydia Vaccine Study: A Potential Game-Changer in Prevention

July 10 at 12:48 PM | tipranks.com

What is Zacks Research's Forecast for Sanofi Q1 Earnings?

July 10 at 9:33 AM | marketbeat.com

Code Waechter LLC Has $660,000 Stake in Sanofi (NASDAQ:SNY)

July 10 at 9:29 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

July 10 at 9:05 AM | gurufocus.com

Bank of New York Mellon Corp Sells 840,093 Shares of Sanofi (NASDAQ:SNY)

July 10 at 4:27 AM | marketbeat.com

Leerink Partnrs Has Strong Estimate for Sanofi Q3 Earnings

July 10 at 2:02 AM | americanbankingnews.com

Sanofi’s Phase 2 Study on SAR444656: A Potential Breakthrough for Hidradenitis Suppurativa

July 9, 2025 | tipranks.com

Sanofi’s Amlitelimab Study: Long-term Safety and Efficacy in Atopic Dermatitis

July 9, 2025 | tipranks.com

Sanofi’s Promising Phase 2 Study on Atopic Dermatitis Treatment: Key Insights for Investors

July 9, 2025 | tipranks.com

Leerink Partnrs Has Negative Forecast for Sanofi Q2 Earnings

July 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, AZN, SNY, NVO, and CSLLY Company Descriptions

AstraZeneca NASDAQ:AZN

$71.13 -0.68 (-0.95%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$71.41 +0.28 (+0.40%)

As of 07/11/2025 07:40 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Bristol Myers Squibb NYSE:BMY

$46.91 -1.61 (-3.32%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$46.88 -0.03 (-0.06%)

As of 07/11/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CSL OTCMKTS:CSLLY

$79.11 -1.62 (-2.01%)

As of 07/11/2025 03:52 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Novo Nordisk A/S NYSE:NVO

$68.93 -2.08 (-2.93%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$68.93 0.00 (0.00%)

As of 07/11/2025 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sanofi NASDAQ:SNY

$48.61 -0.73 (-1.48%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$48.40 -0.20 (-0.42%)

As of 07/11/2025 07:49 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time